• In July 2026, an FDA advisory committee recommended easing compounding restrictions on several peptides, including BPC-157, while Hims & Hers Health announced that long-serving Chief Accounting Officer and Principal Accounting Officer Irene Becklund will resign in October 2026 and remain on as an advisor during the transition.
• The FDA panel’s stance directly affects Hims & Hers Health’s growing peptide operations, including its California compounding facility, potentially widening the range of treatments offered through its telehealth platform.
• We’ll now examine how the FDA’s more permissive view on peptide compounding could influence Hims & Hers Health’s investment narrative and risks.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers, you need to believe its telehealth model can keep turning one-time shoppers into long-term subscribers across weight loss, sexual health and broader wellness. The FDA panel’s softer stance on peptides could support that story by expanding treatment options, while the biggest near term risk remains regulatory and product concentration in a few fast growing categories, including GLP 1s and compounded therapies. The CAO transition looks manageable and is unlikely to change that near term setup in a material way.

The most relevant update here is the FDA advisory committee’s recommendation to ease compounding restrictions on peptides such as BPC 157, which ties directly into Hims & Hers’ growing peptide operations and its California compounding facility. This development sits alongside its GLP 1 and international pushes as a possible additional growth leg, but it also sharpens regulatory and execution risk around quality, compliance and how quickly new offerings can be integrated into the subscription model.

Yet behind the peptide opportunity, investors should also be aware of growing regulatory scrutiny around compounded products and how quickly that could shift if...

Hims & Hers Health's narrative projects $5.6 billion revenue and $211.5 million earnings by 2029. This requires 33.0% yearly revenue growth and a $224.7 million earnings increase from -$13.2 million today.

Uncover how Hims & Hers Health's forecasts yield a $28.42 fair value, a 13% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling about US$5.9 billion of revenue and US$240.7 million of earnings by 2029, but if vertical integration in diagnostics and advanced compounding does not translate into the longer patient lifetimes they expect, this bullish view could prove far too hopeful, especially as the new FDA peptide stance and rising regulatory scrutiny might reshape both upside and downside scenarios in ways those forecasts did not yet reflect.

Explore 27 other fair value estimates on Hims & Hers Health - why the stock might be worth over 5x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.